Europe Injectable Drug Delivery Market

The Europe injectable drug delivery market is projected to reach USD 259.49 billion by 2031 from USD 178.87 billion in 2026, growing at a CAGR of 7.7% during the forecast period.

The increased incidence of chronic diseases, such as cancer, diabetes, autoimmune disorders, and infectious diseases, in major European countries has been driving the demand for biologics, biosimilars, gene therapies, and long-acting injectables. This has created the need for advanced delivery solutions. The migration toward personalized medicine, controlled-release systems, and self-administration therapies has created opportunities for innovation across prefilled syringes, autoinjectors, pen-injectors, wearable on-body devices, and smart connected platforms. These developments are further complemented by the growing adoption of digital health tools, remote patient monitoring, eHealth integration, and data-driven care models, all of which are supported by the EU. Evolving EU regulatory landscape for device regulation, growing biologics manufacturing capacity in the region, gains in home-care treatment models, and increasing collaboration between manufacturers of devices and biopharma companies and CDMOs are pushing the already robust growth of the injectable drug delivery market in Europe even further.

The prominent European injectable drug delivery device manufacturers are BD (US), Baxter (US), Gerresheimer AG (Germany), SCHOTT Pharma (Germany), West Pharmaceutical Services, Inc. (US), among others. Major injectable drug delivery formulation manufacturers in the region are Pfizer Inc. (US), Sanofi (France), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson (US), among others. They have adopted various growth strategies, including organic and inorganic methods, such as product development and strategic partnerships.

To know about the assumptions considered for the study download the pdf brochure

In April 2025, Pfizer Inc. (US) announced the approval of the RSV Vaccine ABRYSVO by the European Commission to help protect adults aged 18-59 against RSV lower respiratory tract disease.

In October 2024, BD (US) collaborated with Ypsomed to advance self-injection solutions for high-viscosity biologic drugs, addressing current limitations by enabling the delivery of higher viscosity (>15cP) biologic drugs in an autoinjector format.

Europe Injectable Drug Delivery Device Manufacturers

BD is a global medical technology leader with a broad product offering that includes medical devices, instruments, systems, and reagents across 190+ countries. The company focuses on three core business segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical includes Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, and Advanced Patient Monitoring. Its Pharmaceutical Systems unit supplies needles, syringes, and IV catheters. The Life Sciences segment includes Integrated Diagnostic Solutions and Biosciences, whereas the Interventional segment encompasses Surgery, Peripheral Intervention, and Urology & Critical Care, focusing on minimally invasive and critical care devices. It has an international presence with subsidiary operations in the US, Canada, and Germany.

Baxter provides a broad product portfolio that extends from medical devices to medicines and biologics. It designs and develops dialysis (acute and chronic), sterile intravenous (IV) solutions, infusion systems, parenteral nutrition products, inhaled anesthetics, generic injectable products, surgical hemostats, and sealants. The company operates mainly through three business segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Pharmaceutical business segment focuses on specialty injectables, inhaled anesthetics, and compounding services primarily for hemophilia, immune system disorders, infections, kidney disorders, trauma, and acute and chronic diseases. Baxter derives a large part of its global operations from North America, Europe, the Middle East & Africa, Latin America, and Asia Pacific.

Europe Injectable Drug Delivery Formulation Manufacturers

Pfizer Inc. is a biopharmaceutical firm engaged in developing, making, and selling biopharmaceuticals, vaccines, and consumer healthcare products. It operates through three main business segments: Biopharma, Pfizer CentreOne, and Pfizer Ignite. Pfizer CentreOne acts as the contract manufacturing organization for specialty APIs. The Biopharma business unit offers core therapeutics and vaccines. In 2024, it was split into Pfizer Oncology, Pfizer US Commercial, and Pfizer International Commercial divisions, with sterile injectables being made available under the International Commercial subsegment. Pfizer maintains a global footprint with operations in more than 40 countries, and its production facilities are strategically located within prominent regions.

Sanofi focuses on researching, developing, manufacturing, and marketing large portfolios of prescription and vaccine products and therapies for various significant medical needs, including immunology, oncology, rare disease, neurology, diabetes, cardiovascular disease, and infectious disease. Its business operations are categorized into two main sectors: Pharmaceuticals and Vaccines. A strong pipeline and R&D efforts have been implemented and continue to support these two sectors, with a strong focus on biologics, immunotherapy, and next-generation platforms. Sanofi Vaccines supplies solutions for pediatric, travel, endemic, and seasonal immunizations.

Market Ranking (Device Manufacturers)

The top device manufacturers in the injectable drug delivery market in Europe are BD (US), Baxter (US), Gerresheimer AG (Germany), SCHOTT Pharma (Germany), and West Pharmaceutical Services, Inc. (US). BD offers prefillable injection drug delivery solutions, safety injection drug delivery devices, and sophisticated platforms functioning with biologics, vaccines, and very high viscous fluids. Baxter offers injectable devices for hospital applications, as well as critical and specialty injectable drug deliveries. Gerresheimer AG is involved in high-precision glass and plastic drug packaging and devices for prefillable injection drug delivery, and customized drug delivery components and devices for injectable drug delivery. SCHOTT Pharma has enhanced its market position with pharmaceutical-grade glass component systems, polymer injection drug deliveries, and highly sophisticated next-generation drug containers for biologics and parenteral therapies. West Pharmaceutical Services continues to lead the market for advanced drug delivery components and prefilled injection delivery device systems.

Market Ranking (Formulation Manufacturers)

The major formulation companies in the injectable drug delivery in Europe are Pfizer Inc. (US), Sanofi (France), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson (US). Pfizer offers a diverse range of sterile injectables and biologics. Its anti-cancer therapies have helped it create dominance in the injectable formulations space. With competence in R&D and biologics manufacturing, Sanofi has built its presence in the market with a wide range of products spanning immunological disorders, diabetes, oncology, and vaccines. Building upon new injectable innovations in cancer and specialty biologics, Novartis AG works to consolidate its presence with dedicated manufacturing facilities for special formulations. F. Hoffmann-La-Roche Ltd. solidifies its leadership with a comprehensive portfolio of HPMCs for injection designed for cancer and immunological disorders, extensive capabilities, and large biologics manufacturing sites. Johnson & Johnson offers advanced injectable therapies to treat immunological disorders, cancer, and neurological disorders.

Related Reports:

Europe Injectable Drug Delivery Market by Product (Device, Self Injection, Formulation, Solution, Emulsions), Formulation Packaging (Ampoules, Bottles), Therapeutic Application (Obesity, Diabetes, Cancer, Psoriasis), Usage Pattern - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com